Grace Therapeutics (GRCE)
NASDAQ:GRCE
Want to see GRCE full AI Analyst Report?
GRCE Stock Chart & Stats
$4.60
-$0.02(-0.47%)
At close: 4:00 PM EST
$4.60
-$0.02(-0.47%)
Day’s Range― - ―
52-Week Range$1.79 - $5.18
Previous CloseN/A
Volume30.96K
Average Volume (3M)58.56K
Market Cap
$33.42M
Enterprise Value$14.75M
Total Cash (Recent Filing)$18.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Jun 23, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding15,474,026
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.58K
Enterprise Value/Ebitda-1.90
Forecast
1Y Price Target
$6.00Price Target Upside30.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$8.55M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces solvency and interest risks, giving management flexibility to fund targeted CMC remediation or additional preclinical work without near-term debt servicing pressure. This durable liquidity buffer supports longer runway versus leveraged peers.
Positive Phase 3 Results And Orphan PositionDemonstrated Phase 3 clinical benefit versus oral nimodipine establishes a clear clinical rationale for adoption in a severe rare indication. Orphan designation plus layered intellectual property creates a structural competitive advantage and potential pricing/market exclusivity if approved.
Defined Regulatory Remediation PathA CRL focused on CMC/nonclinical items (not efficacy) yields a tangible, actionable remediation plan rather than full clinical repetition. That clarity enables targeted resource allocation and a realistic resubmission pathway, reducing open-ended regulatory uncertainty over the medium term.
Bears Say
Pre-revenue And Persistent Cash BurnThe company remains pre-revenue with sustained negative operating and free cash flows, implying ongoing reliance on external financing. This persistent cash burn increases dilution risk and constrains strategic optionality until commercial revenues or significant non-dilutive funding materialize.
Equity Erosion And Negative ReturnsMaterial declines in shareholder equity combined with negative ROE indicate capital is being consumed rather than creating value. This persistent capital erosion weakens the balance sheet cushion, pressures future financing terms, and reflects structural challenges converting R&D investment into profitable growth.
Manufacturing/CMC And Toxicology RisksCMC deficiencies, leachables/toxicology gaps and CMO compliance issues often require extensive testing, remediation or new manufacturing partnerships. These operational fixes can materially extend timelines, increase costs, and complicate supply chain readiness—durable execution risks before commercialization.
Grace Therapeutics News
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.79 and its highest was $5.18 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $33.42M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Jun 23, 2026 which is in 38 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Feb 12, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.23.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 15,474,026 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -1.671%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (30.43% Upside)
$6.00 (30.43% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.10%
12-Months-Change
Fundamentals
Return on Equity
-10.61%
Trailing 12-Months
Asset Growth
11.86%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
GRCE Stock 12 Month Forecast
Average Price Target
$6.00
▲(30.43% Upside)
Technical Analysis
Ownership Overview
8.48%
Insiders
2.72% Mutual Funds
11.46% Other Institutional Investors
74.75% Public Companies and
Individual Investors